Factores pronósticos y predictivos de respuesta a la quimioterapia neoadyuvante con antraciclinas en una serie de cáncer de mama

Research output: Other contribution


Breast cancer is the most common cancer in women worldwide. Neoadjuvant treatment was introduced in cases of locally advanced disease, but in order to increase the number of conservative surgeries, use of neoadjuvant chemotherapy has been extended to earlier stages. This work includes retrospective analysis of 86 cases of patients treated with neoadjuvant chemotherapy according to the decision of the center's Functional Unit of Breast Cancer. All patients received neoadjuvant chemotherapy with a combination schedule of fluorouracil, epirubicin and cyclophosphamide. Chemotherapy is associated with multiple disabling side effects, knowing predictors of response to chemotherapy, we would treat those patients who derive most benefit from it, avoiding the treatment of the rest. We performed immunohistochemical analysis of the estrogen receptor, progesterone receptor, HER-2,Vimentin, cytokeratins 5/6 and Ki6. We correlated results with response, time to progression and survival. Moreover, from the immunohistochemical determination of estrogen and progesterone receptor, HER-2 and Ki67, tumors were classified in luminal A, luminal B, triple negative and HER-2 positive; and assessed the prognostic and predictive value of this classification. Huntingtin Interacting Protein 1 (HIP1) is a lipid-binding protein and clathrina inositol, which interacts with the actin-binding proteins, is considered the first component of the endocytosis machinery, playing an important role in trafficking of clathrina. In recent years, deregulation of endocytosis, have been associated with tumors. The change in the process of endocytosis due to alteration of HIP1, could therefore affect different processes in cancer progression and the response to chemotherapy. In this work we analyze the immunohistochemical expression of HIP1 and its relationship to chemotherapy response, time to progression and survival. Breast cancer susceptibility gene 1 (BRCA1), a gene that is part of the homologous recombination repair, has a role in DNA repair, cell cycle regulation, transcriptional control, the ubiquitination and apoptosis. It has been hypothesized in previous work that low levels of BRCA1 mRNA may predict a better response to chemotherapeutic agents whose mechanism is based on producing DNA alterations, such as anthracyclines or platinum compounds, and yet worse response to agents as taxanes. In our work we evaluated BRCA1 mRNA levels and their relation to the response to chemotherapy, time to progression and survival.
Original languageSpanish
Number of pages149
Place of Publication[Erscheinungsort nicht ermittelbar]
ISBN (Electronic)9788449032059
Publication statusPublished - 2012

Cite this